Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples